-
Sarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
Thursday, February 9, 2017 - 4:13pm | 205Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) dropped 2 percent Thursday on news of the FDA’s approval of Marathon Pharmaceuticals' Duchenne Muscular Dystrophy treatment. Emflaza previously secured priority review and orphan drug status, and the FDA green-lighted the product for...
